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Abstract
Background: To evaluate the clinical outcomes of a group of patients affected by knee osteoarthritis (OA) treated
with MD-Knee (Guna S.p.a., Milan, Italy) versus a group of patients treated with sodium hyaluronate.
Method: This non-inferiority prospective randomized controlled trial involved 60 patients affected by knee OA,
grade 2–3 of Kellgren-Lawrence scale. The MD-Knee Group, Group A (n = 29) was administered five intra-articular
injections at 1 week interval; the sodium hyaluronate Group, Group B (n = 31), was administered five doses of
intra-articular injection of sodium hyaluronate at 1 week interval. All patients were prospectively evaluated before
and at 3 and 6 months after the treatment by the Lequesne Knee Index (LKI) as primary endpoint and the Visual
Analogue Scale (VAS), Pain Killer consumption and SF-36 questionnaires as secondary endpoints.
Results: At the 3- and 6 month follow-up, LKI and VAS improved significantly in both groups compared to baseline
and no statistically significant differences were observed between Group A and Group B. There was no
statistically significant difference in the SF36 questionnaire score and pain killer consumption between two
groups at any time point.
Conclusions: This study shows that both preparations exert similar clinical effects as assessed through
multiple outcome measures. MD-Knee is effective on knee OA symptoms over 6 months after a 5-weekly
injection course, and it is equally effective as the reference sodium hyaluronate.
Trial registration: Trial registration number: ISRCTN93862496. Registration date: January 18th, 2016
Keywords: Osteoarthritis, Knee, Intra-articular, Hyaluronic acid, MD-Knee
Background
Osteoarthritis (OA) is a chronic degenerative joint dis-
ease characterized by progressive damage of articular
cartilage and underlying bone. It is a common rheumatic
disease that affects both sexes and the majority of the
elderly people; nevertheless, also the young are fre-
quently affected by OA, thus becoming an important
cause of lost workdays. Estimated prevalence in general
adult population is of 11 and 24 % for hip and knee OA
respectively [1]. Pain is accentuated by movements and
decreases with rest but, with progression of disease, it
may be present at rest and accompanied by short morn-
ing stiffness; moreover, joint damage causes a progres-
sive functional limitation [2]. In order to reduce pain
and to achieve an overall better clinical condition it is
suggested to use a therapeutic strategy including physical
therapy and rehabilitation, non-steroidal anti-inflammatory
drugs (NSAIDs), analgesics, chondroprotecting agents and
intra-articular treatment with infiltrative substances such as
hyaluronates and steroids. When the disease is at an ad-
vanced stage, orthopedic surgical solution can offer great
benefits [3]. Over the past 10 years some double-blind con-
trolled clinical trials have shown that administration by in-
jection of hyaluronic acid (HA) for 3–5 weeks is superior in
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terms of efficacy, compared to saline, arthrocentesis, and
treatments with NSAIDs [4–6]. In addition, HA has pre-
sented an excellent tolerability profile with a low incidence
of complications at local level and a complete absence of
systemic effects that are typically associated with anti-
inflammatory drugs, steroid or surgery [7, 8]. Among HAs
used, sodium hyaluronate SUPARTZ® (Seikagaku, Tokyo,
Japan) is one of the most used and studied by clinical trials
[9–15]. Other products for intra-articular use have been re-
cently introduced for the treatment of OA; at present time
there is no definitively effective treatment for this condition,
but the very high cost of these therapies, however, fosters
to test new treatments that could provide the same benefits
at a lower cost. Among these, a medical device MD-Knee,
produced by Guna S.p.a., Milan-Italy containing collagen of
porcine origin has been investigated. Collagen content in
MD-Knee has a molecular weight equal to 300,000 dalton,
produced through a process of tangential filtration. It is a
pure product, contaminant-free, with standardized chem-
ical and physical characteristics. Collagen is the most abun-
dant protein in the bodies of mammals, accounting for
approximately 5–6 % of the body weight of an adult man.
About 30 % of total protein mass of higher animals is colla-
gen, found in bones, tendons, joint capsules, muscles, liga-
ments, teeth, skin and in general in extra-cellular matrix.
Porcine tissues have a very high average collagen content,
around 50 %. In collagen amino acid content is for Glycine
22.8, Proline 13.8 and Hydroxy-Proline 13 %. The average
content of other amino acids is only 3 % (max Glutamic
Acid 9.5 %; min Tyrosine 0.4 %). The purpose of an in-situ
introduction of this device is structural; in fact, mechanical
support provided by collagen is an effective natural scaffold
support (bio-scaffold). Its degradation in the constituent
aminoacids seems to constitute a nutritional support for
tissues of the other joint structures [16–19].
The aim of this study is to evaluate the use of collagen
MD-Knee versus sodium hyaluronate (SUPARTZ®) in
patient with knee OA. The outcome has been clinically
assessed through the OMERACT criteria (Outcome
Measures in Rheumatology) [20].
Methods
Study design and patients
JOINT study is a prospective, double blind, multicentric,
randomized clinical trial with active control. The trial
was conducted in accordance with the Good Clinical
Practice (GCP) and the Declaration of Helsinky; the
protocol was approved by the local Ethical Committee
(San Pietro Fatebenefratelli Hospital Bioethic Committee).
Enrollment started in March 2013 and ended in September
2013. Patients were enrolled and followed in both partici-
pating Centers (San Pietro Fatebenefratelli Hospital, Rome,
Italy, and Regina Apostolorum Hospital, Albano Laziale,
Italy). Only patients affected by symptomatic knee OA were
considered eligible for participating in the study. All pa-
tients signed an informed consent before entering the
study. The randomization list was generated through a
high-efficiency system (www.random.org). The list was cre-
ated by generating eight blocks of eight subjects (1: 1) for a
total of 64 enrolled patients. The use of the blocks has
allowed to obtain balanced groups during the study. Two
groups of subjects were identified; the first group (Group
A) consisting of 32 patients has received the investigational
product, MD-Knee (Guna S.p.a., Milan, Italy), The second
group (Group B), consisting in 32 patients, was treated with
SUPARTZ® (Seikagaku, Tokyo, Japan). MD-Knee (injectable
ampoules of 2.0 ml) was administered at a dose of
two vials for a total of 4 ml via intra-articular injec-
tion, once a week for a period of five consecutive
weeks; one vial of 2.5 ml sodium hyaluronate
(SUPARTZ®) was identically administered.
A total of three visits was performed. During the first
one at time T0 (enrollment), the selected patients, after
signing the informed consent, were assigned to the ex-
perimental group (Group A) or to the reference group
(Group B) according to a randomization list. In the same
visit the product under investigation was administered.
All patients then underwent 1 weekly dosing of MD-
Knee or SUPARTZ® for five consecutive weeks; patients
were visited 3 months after enrollment (T3 follow-up)
and 6 months after the start of the trial (T6 follow-up).
The physician performing the intra-articular injection
was aware of the product administered, while both phy-
sicians evaluating the algo-funcional indices, as well as
the patients, were unaware of the product administered.
Inclusion criteria
In this trial were included male and female subjects who
met the following criteria:
 ambulatory adult patients affected by knee OA
 diagnosis according to the ARA (American
Rheumatism Association) criteria
 age > 40 years
 disease activity assessed by the Lequesne Knee
Index ≥ 7.0 at T0
 disease activity assessed according to the VAS at
T0 ≥ 4 cm and persistence of pain in the knee for at
least the last 3 months.
 radiological degree II-III according to the Kellgren-
Lawrence scale
 patients able to comply with study procedures.
Exclusion criteria
Patients who met the following criteria were excluded:
 presence of comorbidities (rheumatoid arthritis,
spondyloarthritis, connective tissue disease,
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polymyalgia rheumatica, gout, Paget’s disease, septic
arthritis, fractures, osteonecrosis, and fibromyalgia)
 patients with skin or subcutaneous tissue infection
in the area of the joint to be treated
 patients who had used oral, parenteral or intra-
articular corticosteroids in the 3 months prior to
the T0 visit
 patients taking topical analgesics that may interfere
with the evaluation of the study
 patients on anticoagulant therapy or suffering from
thrombocytopenia and/or coagulopathy
 patients with allergy to products of porcine origins.
Primary endpoint
At T0 and during the clinical follow-up (FU) at 3 months
and 6 months, it was performed the assessment of the
physical function according to standardized parameters
LKI (Lequesne Knee Index). This clinical trial was set up
as a non-inferiority study of MD-Knee compared to
sodium hyaluronate (SUPARTZ®) in reducing the LKI
score at T3FU in patient with knee OA. At baseline, the
average value of the LKI in both groups was assumed to
be 7.0 ± 1.1. After 3 months, in Group B (SUPARTZ®), it
was expected a reduction of the average value of the LKI
to 4.2 ± 1.1 (e.g., a 40 % reduction from baseline). From
this value of the LKI score, we accepted as non-inferior
a possible value of LKI increased by less than 24 % for
the Group A (MD-Knee), and thus the non-inferiority
margin (NIM) was set equal to 4.2×1.24 = 5.21, with a
standard deviation expected to remain equal to 1.1. Call-
ing D the difference in LKI after 3 months between A
and B (equal to 5:21 to 4:20 = 1.01) product, then null
hypothesis is H0: D ≥ 1.01, while alternative hypothesis is
H1: D <1.01. With these assumptions, the two groups of
29–31 subjects reached a power of 93.8 % in recognizing
the non-inferiority using a one-tailed Student t test with
significance level of α = 0.025. In the case of non-
applicability of the Student’s test, it was estimated that
the power of the non-parametric analogous test (one-
tailed Mann–Whitney U test, with a significance level of
0.025) would have been 92.2 %.
Secondary endpoints
In order to demonstrate the non-inferiority of MD-Knee
in reducing pain, the Visual Analogue Scale (VAS)
(0–10 cm), the LKI score at T6FU, and the Pain
Killer consumption assessment during the course of
the study, were also performed.
Questionnaire SF-36 concerning the state of physical
and mental health of the subjects, was administered and
evaluated for all the patients at T0, T3FU, T6FU. Data
were compared with those obtained by the reference
group (Group B) and had to comply with the specified
threshold for non-inferiority.
Finally, during the investigation period, all events re-
lated with intra-articular injection of the investigational
product were analyzed.
Rescue medication
During the study, the only analgesic allowed was Acet-
aminophen 1000 mg (Pain Killer). Analgesic assump-
tion was reported in a clinical diary.
Reporting adverse events
All information relating to possible adverse events (AEs),
serious adverse events (SAEs) were reported.
Statistical methods
All variables collected were submitted to the appropriate
descriptive analysis, based on their distribution within
the sample recruited, assessed by visual inspection of
distribution histograms and with the Shapiro-Wilk test
for continuous variables, and frequency tables for the
categorical variables. The primary endpoint of the pos-
sible non-inferiority efficacy in reducing the LKI score
(measured at 3 months) in Group A, compared to
Group B, was evaluated with Student’s t test for inde-
pendent data, in a one-tailed test, with the significance
level of 0.025. The variations of scores between groups
obtained from the LKI and the SF36 questionnaire at T0
versus T3FU and versus T6FU were analyzed with re-
peated measures ANOVA and Bonferroni-adjusted post-
hoc test for pairwise comparisons. The changes in the
LKI score intra-groups, at T0, versus T3FU and versus
T6FU, were analyzed by repeated measures ANOVA
plus Bonferroni post-hoc tests.
The change in VAS inter-groups at T0 versus T3FU
and versus T6FU, were also analyzed by repeated mea-
sures ANOVA, with Bonferroni post-hoc tests. Pain
Killer consumption was evaluated with the Mann–Whit-
ney U test, after having standardized the values col-
lected. The adverse events in each group were tabulated,
and their frequency of occurrence was compared with
Fisher’s exact test.
Results of test were considered statistically significant
if p <0.05, unless for the primary endpoint, for which a
one-tailed test with p < 0.025 was considered the level of
statistical significance. All analyses were carried out with
the statistical package Stata/SE 13.1 (The StataCorp LP,
4905 Lakeway Drive, College Station, Texas 77845 USA).
Results
Sixty-seven patients were assessed for eligibility. Three
patients were excluded for not meeting the inclusion
criteria, as affected by systemic inflammatory arhtritis (2
rheumatoid arthritis, 1 psoriatic arthritis). As reported
previously 32 patients in Group A (MD-Knee) and 32
patients in Group B (SUPARTZ®) were enrolled. The
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patients’ demographic characteristics at T0 are shown in
Table 1, evidencing no difference between groups.
Women included in Group A were 86.2 and 64.5 % in
Group B; mean age was similar in both groups (approxi-
mately 69 years). Body Mass Index (BMI) was also simi-
lar in both groups, with patients moderately overweight
(average BMI approximately 27 kg/m2). Kellgren and
Lawrence radiological grades II and III were similarly
distributed. Function evaluation showed LKI score ap-
proximately 12.5. Knee OA symptoms were moderate to
severe (average VAS 7.5 cm circa). There was no differ-
ence between Group A and Group B in SF36 question-
naire score at T0 (Table 1) and NSAIDs consumption in
the previous 3 months (Mann–Whitney U test: p =
0.8439) (data not shown). Three patients in the MD-
Knee arm and one patient in the SUPARTZ arm
dropped out before study conclusion. In the MD-Knee
one patient experienced joint pain after the second
intra-articular injection of MD-knee and decided to
withdraw from the study, with knee pain regressing in
1 day without the need of any medicaments and no signs
of joint effusion/inflammation, one patient experienced a
direct blunt trauma in the knee after the second MD-
knee injection and was then excluded from study pros-
ecution and one patient was lost to followup. In the
SUPARTZ group, one patient experienced an accidental
fall with multiple contusions, involving studied knee,
after the third injection of SUPARTZ and was then ex-
cluded from the study (Fig. 1).
Primary endpoint
Non-inferiority of LKI score at T3FU
LKI score was the same in the two groups at T0
(Student’s t test: p = 0.8871) and at T3FU (Student’s t test:
p = 0.3302). Observed difference intra-groups (T3FU
mean LKI - T0 mean LKI) was larger in absolute value in
Group A (MD-Knee) than in Group B (SUPARTZ®), but
this difference was not significant (Welch’s test: p =
0.3683). The mean difference between Group A and
Group B was equal to − 3.7778 - (−2.9483) = −0.8295, and
the confidence interval (CI) 95 % of this difference ranged
from − 2.6737 to +1.0147, while the standard error was
0.9110. Since the variances at T3FU did not differ between
groups (F-test: p = 0.7540), the variance and the standard
error pooled were used, keeping the non-inferiority limit
by 24 % compared to the value measured in Group B, as
established by the protocol. The precise difference be-
tween the average score was then − 1.2005, while the
interval difference, taking into account the degrees of free-
dom of the system (dof = 54), was included with the 99 %
confidence between − 4.47004 and +2.06904, and since the
non-inferiority limit calculated for the differences between
averages was +2.3503, we could conclude that the treat-
ment with MD-Knee was not inferior of the treatment
with SUPARTZ®, with a confidence level higher than 99 %.
Table 2 – Fig. 2
Secondary endpoints
 LKI variation inter- groups at T0 versus T6FU
Repeated measures ANOVA of LKI showed a
significant reduction intra-patient (F-test: p <0.01),
even assuming the non-sphericity of the data. It was
observed no change due to membership in the treat-
ment group (F-test: p = 0.621). Table 2 - Fig. 2
 Pain VAS
Repeated measures ANOVA of VAS showed a
intra-patient highly significant variation, while
inter-groups variation (p = 0.275) and interaction
(group x factor) (p = 0.447) are not significant.
Therefore VAS variation does not seem to depend
on the administered treatment. Table 2 – Fig. 3
 SF36 questionnaire
Repeated measures ANOVA of SF36 questionnaire
total score showed a significant change intra-patient
(F-test: p = 0.005, without assuming the sphericity of
the data), while no changes were observed due to
treatment (F-test: p = 0.462) at T3FU and T6FU.
Table 2 - Fig. 4
 Pain Killer consumption (Rescue Medication)
Including dropouts, Acetaminophen was used by
13 of 29 patients (44,8 %) in Group A (MD-Knee)
and by 12 of 31 patients (38,7 %) in Group B
(SUPARTZ®). Acetominophen consumption during
the trial did not change in the two Groups,
considering both “only users” and “all patients”
(Mann–Whitney test U: p = 0.2198 e p = 0.9348,
respectively). Fig. 5a, b.
Safety
Adverse events (AE) observed by the investigators or re-
ported by the patients spontaneously or following a non-





Age (years ± SD) 69.41 ± 8.42 69.97 ± 9.5
Women, n (%) 25 (86.2 %) 20 (64.5 %)
BMI (kg/m2) 27.20 ± 3.78 27.3 ± 3.56
Kellgren and Lawrence,
n (%)Grade II (%)
15 (51 %) 17 (55 %)
Kellgren and Lawrence,
n (%)Grade III (%)
14 (49 %) 14 (45 %)
LKI ± SD 12.48 ± 2.63 12.6 ± 3.48
SF36 ± SD 91.41 ± 20.01 93.07 ± 17.3
Pain VAS (cm) ± SD 7.67 ± 1.41 7.42 ± 1.35
Data are mean ± SD Standard Deviation unless otherwise indicated. BMI Body
Mass Index, LKI Lequesne Knee Index, VAS Visual Analogue Scale
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leading question, were investigated. Treatment with
MD-Knee and with SUPARTZ® for up to 6 months was
generally well tolerated. No systemic adverse events and
septic complication were observed. Only one subject
discontinued for a moderate post-injection reaction in
Group A (MD-Knee) but symptoms disappeared without
the need of medication. No joint effusion events were
observed throughout the entire followup of patients in
both groups.
Discussion
Intra-articular (IA) therapy in the treatment of OA knee
is widespread in clinical practice, although much de-
bated by the evidences of the most recent international
recommendations. The IA therapy may consist of corti-
costeroids, of high or low molecular weight (MW) HA,
of polynucleotited, pletelet-rich-plasma (PRP) or other
substances including collagen extracts. Recent scientific
evidences suggest that injecting treatment with porcin
collagen could provide interesting improving clinical
performances [16–19]. However IA therapy should be
considered with the complex management of OA, such
as medical and non- medical interventions. I The colla-
gen administered at intra-articular level could stimulate
and promote the healing process of the cartilage matrix,
which is injured in the course of osteoarthritis, as dem-
onstrated in animal models [17]. Collagen can promote
repair processes of the cartilage matrix, interrupting the
degenerative process and articular damage, which causes
inflammation and pain.
In this double-blind, randomised, active-controlled
clinical trial in patients affected by knee OA, five
intra-articular injections of MD-Knee or sodium hyalur-
onate administered weekly are equally able to improve
Assessed for eligibility (n= 67)
Excluded  (n= 3)
♦ Not meeting inclusion criteria (n=3)
♦ Declined to participate (n=0)
♦ Other reasons (n=0)
Randomized (n=64)
Allocated to intervention Supartz (n=32)
♦ Received allocated intervention (n=32)
♦ Did not receive allocated intervention (n=0)
Allocated to intervention MD-Knee (n=32)
♦ Received allocated intervention (n=32)
♦ Did not receive allocated intervention  (n=0)
Lost to follow-up (n=1)
Discontinued intervention (n=2) 1 direct knee 
trauma, 1 post-injection pain
Lost to follow-up (n=0)
Discontinued intervention (n=1) 1 accidental 
fall with knee trauma
Analysed  (n=31)
♦ Excluded from analysis (n=0)
Analysed  (n=29)
♦ Excluded from analysis (n=0)
Fig. 1 Flow chart reporting patients’ enrollment and study prosecution with drop outs and reasons for drop out
Table 2 Data are mean ± SD (Standard Deviation) at T3FU and T6FU with p value
T3 FU T6 FU
Group A (MD-Knee) Group B (SUPARTZ®) P-value Group A (MD-Knee) Group B (SUPARTZ®) P-value
LKI ± SD 8.59 ± 4.71 9.79 ± 4.43 0.33 9.12 ± 3.89 9.28 ± 4.28 0.621
Pain VAS ± SD 5.26 ± 2.52 5.13 ± 2.41 NE 5.42 ± 2.69 4.43 ± 2.63 0.275
SF36 ± SD 99.15 ± 8.95 101.32 ± 6.37 NE 88.37 ± 28.83 92.07 ± 23.37 0.462
NE Not evaluated
Martin Martin et al. BMC Musculoskeletal Disorders  (2016) 17:94 Page 5 of 8
function and reduce pain after 3 months till at least
6 months by the end of treatment. As shown VAS and
LKI improved at T3FU and T6FU. SF36 questionnaire,
and pain killer consumption did not change in both
groups confirming non-inferiority hypothesis. We have to
acknowledge limitations of this study. In this non inferior-
ity prospective randomized controlled double blind study,
for bio-ethical reasons, we have no placebo arm, therefore
the confrontation was made between two active arms
only. Also, followup time was limited to 6 months only,
while longer followups are recommended for chronic
pathologies such as OA.
Future trials should investigate the proportion of
OARSI/OMERACT criteria responders which might be
useful for an indirect comparison with other local or sys-
temic treatments; also the effect on the progression of
tissue damage could be looked into. The lack of a pla-
cebo control group is to be expected when IA injections
of hyaluronic acid products are routinely used in clinical
practice. A further issue concerns the nature of placebo
for IA injections, ie. use of saline solution or sham injec-
tion. For these ethical and methodological reasons, it
has been considered correct to compare MD-Knee with
a marketed product, such as SUPARTZ®, that has been
widely used in clinical practice and proved effective in
previous studies. Moreover the lack of comparison with
patients treated with other kind of HA (as high MW or
cross-linked HA) doesn’t allow us to draw final conclu-
sion about the range of efficacy of MD-Knee Guna Med-
ical Device, since the clinical equivalence of all HA
products is not clear. Nevertheless a favourable feature
of this trial is assessing OA knee symptoms effectiveness
through several different measures, providing a wide
clinical evaluation. Beside all Lequesne’s items showing a
similar advantage for both groups. Further studies are
warranted in order to verify whether the symptomatic
effect of MD-Knee is associated with a halting of knee
OA progression.
Fig. 2 Variation of LKI (Lequesne Knee Index) score intra-subject and inter-groups at time T0; T3FU; T6FU
Fig. 3 Visual Analogue Scale (VAS) at time T0; T3FU; T6FU for Group ARTZ® and in Group MD-Knee
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Fig. 4 SF36 questionnaire. Score at time T0; T3FU; T6FU for Group ARTZ®and Group MD-Knee
Fig. 5 a Pain Killer consumption (days), in users only, in both groups. b Pain Killer consumption (days),in all subject, in both groups
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Conclusion
This trial shows that MD-Knee preparation is effective
on knee OA symptoms over 6 months after a 5-week in-
jection course, and it is equally effective in improving
clinical performance as assessed through LKI, VAS, SF36
questionnaire and Pain Killer consumption, as the refer-
ence HA formulation.
MD-Knee and SUPARTZ® were equally well tolerated
both locally and at a systemic level, therefore showing a
satisfactory safety profile.
The reduced cost of MD-Knee compared to low or
high MW HA could allow wider use of IA therapy,
resulting in a NSAIDs intake reduction, as well as social
cost reduction due to working days lost and caregivers
time off work.
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